"All-in-one Cells" for Regenerative Medicine: Introduction to the iPS Cell Research Institute, Kyoto University.

Induced cynic stem cells (iPS cells) have shown great potential in areas such as regenerative medicine since they were invented more than a decade ago by Kyoto University professor Tsahmi Yamano, and clinical studies have been successful.
, Xinhua News Agency reporters visited the iPS Cell Research Institute at Kyoto University in Japan, the forefront of regenerative medicine, to listen to Yamano and his team talk about the importance of iPS cell research.
2012, Yamano Yamano, a professor at Kyoto University in Japan, won the Nobel Prize in Physiology or Medicine for his contribution to iPS cells, and iPS cell research has been increasingly in the public eye since then.
iPS cells are regarded as "all-powerful cells" of regenerative medicine because of their infinite proliferation and multi-way differentiation potential.
According to Dr. Nei Caixiang of kyoto University's iPS Cell Research Institute, iPS cells were first genetically edited and recombined in 2006 and 2007 using laboratory mice and human somatic cells, respectively, to return to the state of multi-differentiated stem cells.
iPS cells avoid ethical issues in embryonic stem cell research and have great potential for medical applications such as retinal disease, cardiomyopathy, Parkinson's disease, and can also be used in the study of various disease mechanisms and the development of new drugs. according to
, the institute's 2030 goals include universal regenerative medicine based on the iPS cell bank, personalized medical treatment using iPS cells, and the development of new drugs for some incurable diseases, and the use of iPS cells to open up new life sciences and medical fields.
the iPS Cell Institute at Kyoto University, which was founded in 2010 with about 150 researchers, the number of team members has grown to 500, and Kyoto University has built several new research buildings for the institute.
, while japan's basic science researchers generally bemoan the lack of access to research funding, the iPS Cell Institute is a fertile ground.
understood that the Japanese government has regenerative medicine and other cutting-edge medical technology as an important pillar of the "new economic growth strategy" spare no effort to support.
2013, the Japanese government said it would invest about 110 billion yen (about 114 yen) in iPS cell research over the next 10 years.
brief exchange with Yamano, he learned that the use of iPS cells in regenerative medicine was progressing earlier than he had expected.
he used human cells to grow iPS cells in 2007.
in the past seven years alone, the Takahashi team at the Japan Institute of Science and Chemistry has achieved the clinical application of iPS cells for the first time.
In order to be able to use iPS cells more efficiently, Yamanoka and others and the Japanese Red Cross have worked together to establish iPS cell bank, using a small number of blood cells and other cells to make iPS cells and save them, can be faster and cheaper to carry out transplant research and applications.
that the use of iPS cells in clinical studies is risky and that researchers will try to assess the risk before conducting clinical applications.
Knut Weltjian, a Canadian associate professor at Kyoto University's iPS Cell Institute, says they are careful to advance every step of the study, constantly evaluating iPS cells and their efficacy before pushing iPS cell research to clinical and therapeutic methods.
.